Collegium Pharmaceutical (COLL) Stock Overview
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
COLL Community Fair Values
Create NarrativeSee what 20 others think this stock is worth. Follow their fair value or set your own to get alerts.
Collegium Pharmaceutical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$39.11 |
| 52 Week High | US$42.29 |
| 52 Week Low | US$23.23 |
| Beta | 0.68 |
| 1 Month Change | 20.67% |
| 3 Month Change | 35.52% |
| 1 Year Change | 7.86% |
| 3 Year Change | 121.34% |
| 5 Year Change | 114.89% |
| Change since IPO | 218.23% |
Recent News & Updates
Recent updates
Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) P/E Still Appears To Be Reasonable
Jul 31
There May Be Reason For Hope In Collegium Pharmaceutical's (NASDAQ:COLL) Disappointing Earnings
May 16Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Has Caught The Eye Of Investors
Apr 07Collegium Pharmaceutical: Checking The Boxes
Mar 03Improved Revenues Required Before Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Find Their Feet
Dec 24Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion
Nov 26Shareholders Can Be Confident That Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are High Quality
Nov 14Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?
Oct 28
Ironshore Acquisition And Calculated Moves Set To Propel Growth In ADHD Market
Collegium Pharmaceutical's acquisition of Ironshore Therapeutics positions them in the ADHD market, aiming for revenue growth through diversified offerings and operational efficiencies.Collegium Pharmaceutical: Diversifying And Growing
Aug 09Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking
Jul 24Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly
Jun 05Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'
May 13It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package
May 10Collegium Pharmaceutical Q4: The Beat Goes On
Feb 26These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well
Feb 24There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues
Jan 05Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly
Nov 12Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?
Aug 09Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?
Mar 10Shareholder Returns
| COLL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 3.6% | 2.0% | 0.5% |
| 1Y | 7.9% | -12.9% | 15.7% |
Return vs Industry: COLL exceeded the US Pharmaceuticals industry which returned -13% over the past year.
Return vs Market: COLL underperformed the US Market which returned 15.1% over the past year.
Price Volatility
| COLL volatility | |
|---|---|
| COLL Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 10.2% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: COLL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: COLL's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 357 | Vikram Karnani | www.collegiumpharma.com |
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company’s portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003.
Collegium Pharmaceutical, Inc. Fundamentals Summary
| COLL fundamental statistics | |
|---|---|
| Market cap | US$1.24b |
| Earnings (TTM) | US$36.27m |
| Revenue (TTM) | US$707.01m |
Is COLL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COLL income statement (TTM) | |
|---|---|
| Revenue | US$707.01m |
| Cost of Revenue | US$88.30m |
| Gross Profit | US$618.71m |
| Other Expenses | US$582.44m |
| Earnings | US$36.27m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.15 |
| Gross Margin | 87.51% |
| Net Profit Margin | 5.13% |
| Debt/Equity Ratio | 407.2% |
How did COLL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/22 19:17 |
| End of Day Share Price | 2025/08/22 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Collegium Pharmaceutical, Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dana Flanders | Guggenheim Securities, LLC |
| Antonio Arce | H.C. Wainwright & Co. |
| Oren Livnat | H.C. Wainwright & Co. |